Background: Polycystic ovary syndrome (PCOS) is a hormonal imbalance resulting from high levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in females, leading to immature eggs, ovarian cysts, irregular menstrual cycles, infertility, excessive facial hair growth, and acne. Objective: This study was conducted to follow up the therapeutic effect on some blood, hormonal, and immune variables of samples consisting of 35 patients with polycystic ovary syndrome (PCOS) from women suffering from infertility and infertility, and who visited Azadi Teaching Hospital and private laboratories in Kirkuk city, their ages ranged between (18 - 40 years). Materials and Methods: Sample collection and follow-up began by observing some clinical signs in addition to verifying the results of ultrasound examinations from early February 2023 to early November 2023. Each patient’s examinations were followed up before treatment and three months after taking the treatment. The results we obtained after three months of treatment were compared with the results of the examinations of the patients in the pre-treatment stage and the control group. The treatment plan was based on modifying the patient's dietary lifestyle by following a healthy diet and giving treatment consisting of oral contraceptives, fertility drugs and the use of sugar-reducing drugs such as Glucophage or Metformin, in addition to nutritional supplements such as antioxidants. Result: The results of the therapeutic effect on the patients' diagnostic clinical signs showed a significant decrease in their percentages after three months of treatment compared to the pre-treatment stage such as (ovulation disorders - menstrual disorders - obesity - hirsutism - acne -). The results of the statistical analysis of the study showed that the therapeutic effect showed a significant difference in the body mass index (BMI) after three months of treatment compared to the pre-treatment stage and the control group. The therapeutic effect of the immune factors for each Hast Shock protein 70 and Interleukin-17 also showed a significant decrease at the level (0.000 > p) respectively after three months of taking the treatment compared to the pre-treatment stage and the control group. It was found that there is a significant positive correlation between the level of Heat Shock Protein 70 and the cellular kinetic IL-17.